Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
14
02
2023
accepted:
09
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
8
5
2024
Statut:
aheadofprint
Résumé
Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders
Identifiants
pubmed: 38720072
doi: 10.1038/s41586-024-07403-2
pii: 10.1038/s41586-024-07403-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399–408 (2018).
pubmed: 29119217
doi: 10.1007/s00213-017-4771-x
Armstrong, S. B. et al. Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces veterans. Mil. Psychol. https://doi.org/10.1080/08995605.2022.2156200 (2023).
Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637–1648 (2022).
pubmed: 36322843
doi: 10.1056/NEJMoa2206443
Cameron, L. P. et al. 5-HT
Krebs-Thomson, K., Ruiz, E. M., Masten, V., Buell, M. & Geyer, M. A. The roles of 5-HT
pubmed: 17013638
doi: 10.1007/s00213-006-0566-1
Schwelm, H. M. et al. Qualitative and quantitative analysis of tryptamines in the poison of Incilius alvarius (Amphibia: Bufonidae). J. Anal. Toxicol. 46, 540–548 (2022).
pubmed: 33851996
doi: 10.1093/jat/bkab038
Hughes, Z. A. et al. Neurochemical evaluation of the novel 5-HT
pubmed: 15740724
doi: 10.1016/j.ejphar.2005.01.018
Loane, C. & Politis, M. Buspirone: what is it all about? Brain Res. 1461, 111–118 (2012).
pubmed: 22608068
doi: 10.1016/j.brainres.2012.04.032
Winter, J. C., Filipink, R. A., Timineri, D., Helsley, S. E. & Rabin, R. A. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol. Biochem. Behav. 65, 75–82 (2000).
pubmed: 10638639
doi: 10.1016/S0091-3057(99)00178-1
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P. & Griffiths, R. R. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am. J. Drug Alcohol Abuse 45, 161–169 (2019).
pubmed: 30822141
pmcid: 6430661
doi: 10.1080/00952990.2018.1545024
Reckweg, J. T. et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J. Neurochem. 162, 128–146 (2022).
pubmed: 35149998
pmcid: 9314805
doi: 10.1111/jnc.15587
Chauhan, M., Parry, R. & Bobo, W. V. Vilazodone for major depression in adults: pharmacological profile and an updated review for clinical practice. Neuropsychiatr. Dis. Treat. 18, 1175–1193 (2022).
pubmed: 35726313
pmcid: 9206504
doi: 10.2147/NDT.S279342
Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled 5-HT
pubmed: 32946782
pmcid: 7593816
doi: 10.1016/j.cell.2020.08.024
Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377–389.e12 (2017).
pubmed: 28129538
pmcid: 5289311
doi: 10.1016/j.cell.2016.12.033
Cameron, L. P. et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589, 474–479 (2021).
pubmed: 33299186
doi: 10.1038/s41586-020-3008-z
Kaplan, A. L. et al. Bespoke library docking for 5-HT
pubmed: 36171289
pmcid: 9996387
doi: 10.1038/s41586-022-05258-z
Carhart-Harris, R. L. & Nutt, D. J. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091–1120 (2017).
pubmed: 28858536
pmcid: 5606297
doi: 10.1177/0269881117725915
Olsen, R. H. J. et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat. Chem. Biol. 16, 841–849 (2020).
pubmed: 32367019
pmcid: 7648517
doi: 10.1038/s41589-020-0535-8
Nichols, D. E. Chemistry and structure–activity relationships of psychedelics. Curr. Top. Behav. Neurosci. 36, 1–43 (2018).
pubmed: 28401524
Glennon, R. A. et al. Binding of β-carbolines and related agents at serotonin (5-HT
pubmed: 10940539
doi: 10.1016/S0376-8716(99)00148-9
Halberstadt, A. L. & Geyer, M. A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61, 364–381 (2011).
pubmed: 21256140
pmcid: 3110631
doi: 10.1016/j.neuropharm.2011.01.017
Xu, P. et al. Structural insights into the lipid and ligand regulation of serotonin receptors. Nature 592, 469–473 (2021).
pubmed: 33762731
doi: 10.1038/s41586-021-03376-8
Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure–function relations in G protein-coupled receptors. Methods Neurosci. 25, 366–428 (1995).
doi: 10.1016/S1043-9471(05)80049-7
Rasmussen, S. G. et al. Crystal structure of the β
pubmed: 21772288
pmcid: 3184188
doi: 10.1038/nature10361
Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615–619 (2013).
pubmed: 23519215
pmcid: 3644390
doi: 10.1126/science.1232808
Nichols, D. E., Monte, A., Huang, X. & Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Res. 73, 117–119 (1996).
pubmed: 8788487
doi: 10.1016/0166-4328(96)00080-0
Speeter, M. E. & Anthony, W. C. The action of oxalyl chloride on indoles—a new approach to tryptamines. J. Am. Chem. Soc. 76, 6208–6210 (1954).
doi: 10.1021/ja01652a113
Shulgin, A. T. & Shulgin, A. Tihkal: The Continuation (Transform Press, 1997).
Kozell, L. B. et al. Pharmacologic activity of substituted tryptamines at 5-hydroxytryptamine (5-HT)
pubmed: 36669875
pmcid: 10029822
doi: 10.1124/jpet.122.001454
Blair, J. B. et al. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J. Med. Chem. 43, 4701–4710 (2000).
pubmed: 11101361
doi: 10.1021/jm000339w
Laban, U., Kurrasch-Orbaugh, D., Marona-Lewicka, D. & Nichols, D. E. A novel fluorinated tryptamine with highly potent serotonin 5-HT
pubmed: 11277522
doi: 10.1016/S0960-894X(01)00062-2
Wang, C. et al. Structural basis for molecular recognition at serotonin receptors. Science 340, 610–614 (2013).
pubmed: 23519210
pmcid: 3644373
doi: 10.1126/science.1232807
Gasser, P., Kirchner, K. & Passie, T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57–68 (2015).
pubmed: 25389218
doi: 10.1177/0269881114555249
Halberstadt, A. L., Koedood, L., Powell, S. B. & Geyer, M. A. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J. Psychopharmacol. 25, 1548–1561 (2011).
pubmed: 21148021
doi: 10.1177/0269881110388326
Darmani, N. A., Martin, B. R., Pandey, U. & Glennon, R. A. Do functional relationships exist between 5-HT
pubmed: 2145593
doi: 10.1016/0091-3057(90)90098-3
Arnt, J. & Hyttel, J. Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT
pubmed: 2524390
doi: 10.1016/0014-2999(89)90178-7
Ermakova, A. O., Dunbar, F., Rucker, J. & Johnson, M. W. A narrative synthesis of research with 5-MeO-DMT. J. Psychopharmacol. 36, 273–294 (2022).
pubmed: 34666554
doi: 10.1177/02698811211050543
Bagot, R. C. et al. Ketamine and imipramine reverse transcriptional signatures of susceptibility and induce resilience-specific gene expression profiles. Biol. Psychiatry 81, 285–295 (2017).
pubmed: 27569543
doi: 10.1016/j.biopsych.2016.06.012
Berton, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864–868 (2006).
pubmed: 16469931
doi: 10.1126/science.1120972
Donahue, R. J., Muschamp, J. W., Russo, S. J., Nestler, E. J. & Carlezon, W. A. Jr. Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol. Psychiatry 76, 550–558 (2014).
pubmed: 24495460
pmcid: 4087093
doi: 10.1016/j.biopsych.2013.12.014
Golden, S. A., Covington, H. E. 3rd, Berton, O. & Russo, S. J. A standardized protocol for repeated social defeat stress in mice. Nat. Protoc. 6, 1183–1191 (2011).
pubmed: 21799487
pmcid: 3220278
doi: 10.1038/nprot.2011.361
Krishnan, V. et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391–404 (2007).
pubmed: 17956738
doi: 10.1016/j.cell.2007.09.018
Willner, P., Towell, A., Sampson, D., Sophokleous, S. & Muscat, R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 93, 358–364 (1987).
pubmed: 3124165
doi: 10.1007/BF00187257
Li, N. et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754–761 (2011).
pubmed: 21292242
pmcid: 3068225
doi: 10.1016/j.biopsych.2010.12.015
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B. & Thompson, S. M. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2022489118 (2021).
Shao, L. X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535–2544.e4 (2021).
pubmed: 34228959
pmcid: 8376772
doi: 10.1016/j.neuron.2021.06.008
de la Fuente Revenga, M. et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 37, 109836 (2021).
pubmed: 34686347
doi: 10.1016/j.celrep.2021.109836
Savalia, N. K., Shao, L. X. & Kwan, A. C. A dendrite-focused framework for understanding the actions of ketamine and psychedelics. Trends Neurosci. 44, 260–275 (2021).
pubmed: 33358035
doi: 10.1016/j.tins.2020.11.008
Bickle, J. G. et al. 5HT
Newman-Tancredi, A. et al. NLX-112, a highly selective 5-HT
pubmed: 29555239
doi: 10.1016/j.brainres.2018.03.016
Becker, A. M. et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Int. J. Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyac075 (2022).
Strassman, R. J. Human psychopharmacology of N,N-dimethyltryptamine. Behav. Brain Res. 73, 121–124 (1996).
pubmed: 8788488
doi: 10.1016/0166-4328(96)00081-2
Pokorny, T., Preller, K. H., Kraehenmann, R. & Vollenweider, F. X. Modulatory effect of the 5-HT
pubmed: 26875114
doi: 10.1016/j.euroneuro.2016.01.005
Reckweg, J. et al. A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in healthy volunteers. Front. Pharmacol. 12, 760671 (2021).
pubmed: 34912222
pmcid: 8667866
doi: 10.3389/fphar.2021.760671
Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400–1411 (2003).
pubmed: 12784105
doi: 10.1038/sj.npp.1300203
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
pubmed: 28250466
pmcid: 5494038
doi: 10.1038/nmeth.4193
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
pubmed: 28165473
doi: 10.1038/nmeth.4169
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
pubmed: 33257830
doi: 10.1038/s41592-020-00990-8
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
pubmed: 20383002
pmcid: 2852313
doi: 10.1107/S0907444910007493
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861–877 (2019).
pubmed: 31588918
pmcid: 6778852
doi: 10.1107/S2059798319011471
Yamashita, K., Palmer, C. M., Burnley, T. & Murshudov, G. N. Cryo-EM single-particle structure refinement and map calculation using Servalcat. Acta Crystallogr. D Struct. Biol. 77, 1282–1291 (2021).
pubmed: 34605431
pmcid: 8489229
doi: 10.1107/S2059798321009475
The PyMOL Molecular Graphics System v.2.0 (Schrödinger, 2017).
Kroeze, W. K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362–369 (2015).
pubmed: 25895059
pmcid: 4424118
doi: 10.1038/nsmb.3014
Henke, A. et al. Toward serotonin fluorescent false neurotransmitters: development of fluorescent dual serotonin and vesicular monoamine transporter substrates for visualizing serotonin neurons. ACS Chem. Neurosci. 9, 925–934 (2018).
pubmed: 29281252
doi: 10.1021/acschemneuro.7b00320
Rodrı́guez, P. et al. A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats. ACS Chem. Neurosci. 11, 1661–1672 (2020).